利福霉素对性传播细菌病原体的活性。
Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens.
机构信息
Nabriva Therapeutics GmbH, Vienna, Austria
Nabriva Therapeutics GmbH, Vienna, Austria.
出版信息
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02380-17. Print 2018 May.
Abstract
The pleuromutilin antibiotic lefamulin demonstrated activity against the most relevant bacterial pathogens causing sexually transmitted infections (STI), including (MIC, 0.02/0.04 mg/liter; = 15), susceptible and multidrug-resistant (MIC range, 0.002 to 0.063 mg/liter; = 6), and susceptible and resistant (MIC, 0.12/0.5 mg/liter; = 25). The results suggest that lefamulin could be a promising first-line antibiotic for the treatment of STI, particularly in populations with high rates of resistance to standard-of-care antibiotics.
摘要
黏菌素类抗生素雷莫拉宁对引起性传播感染（STI）的最相关细菌病原体具有活性，包括（MIC，0.02/0.04 毫克/升；=15），对敏感和多药耐药（MIC 范围，0.002 至 0.063 毫克/升；=6）和敏感和耐药（MIC，0.12/0.5 毫克/升；=25）的均具有活性。这些结果表明，雷莫拉宁可能是治疗 STI 的一种有前途的一线抗生素，特别是在对标准治疗抗生素耐药率较高的人群中。
相似文献
1
Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens.
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02380-17. Print 2018 May.
2
Periodic Presumptive Treatment for Vaginal Infections May Reduce the Incidence of Sexually Transmitted Bacterial Infections.
J Infect Dis. 2016 Jun 15;213(12):1932-7. doi: 10.1093/infdis/jiw043. Epub 2016 Feb 4.
3
Prevalence of Mycoplasma genitalium and other sexually transmitted infections causing urethritis among high-risk heterosexual male patients in Estonia.
Infect Dis (Lond). 2018 Feb;50(2):133-139. doi: 10.1080/23744235.2017.1366044. Epub 2017 Sep 4.
4
Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.
Pharmacotherapy. 2018 Sep;38(9):935-946. doi: 10.1002/phar.2166. Epub 2018 Aug 20.
5
Antimicrobial treatment and resistance in sexually transmitted bacterial infections.
Nat Rev Microbiol. 2024 Jul;22(7):435-450. doi: 10.1038/s41579-024-01023-3. Epub 2024 Mar 20.
6
Tissue Distribution of [C]-Lefamulin into the Urogenital Tract in Rats.
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0035522. doi: 10.1128/aac.00355-22. Epub 2022 Jul 11.
7
Identifying a consensus sample type to test for Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis and human papillomavirus.
Clin Microbiol Infect. 2018 Dec;24(12):1328-1332. doi: 10.1016/j.cmi.2018.03.013. Epub 2018 Mar 17.
8
Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium in asymptomatic patients under 30 years of age screened in a French sexually transmitted infections clinic.
Eur J Dermatol. 2014 Sep-Oct;24(5):611-6. doi: 10.1684/ejd.2014.2413.
9
In vitro activity of lomefloxacin against Chlamydia trachomatis, Neisseria gonorrhoeae, Haemophilus ducreyi, Mycoplasma hominis, and Ureaplasma urealyticum.
Diagn Microbiol Infect Dis. 1989 May-Jun;12(3 Suppl):83S-86S. doi: 10.1016/0732-8893(89)90071-0.
10
In vitro activity of temafloxacin against pathogens causing sexually transmitted diseases.
Am J Med. 1991 Dec 30;91(6A):24S-26S. doi: 10.1016/0002-9343(91)90305-h.
引用本文的文献
1
test of the novel antibiotic lefamulin alone and in combination with doxycycline against .
Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0134624. doi: 10.1128/aac.01346-24. Epub 2024 Dec 13.
2
Phenotypic antibiotic resistance of Mycoplasma genitalium and its variation between different macrolide resistance-associated mutations.
J Antimicrob Chemother. 2025 Feb 3;80(2):465-471. doi: 10.1093/jac/dkae430.
3
In Vivo Immune-Modulatory Activity of Lefamulin in an Influenza Virus A (H1N1) Infection Model in Mice.
Int J Mol Sci. 2024 May 15;25(10):5401. doi: 10.3390/ijms25105401.
4
Treatment of bacterial sexually transmitted infections in Europe: gonorrhoea, , and syphilis.
Lancet Reg Health Eur. 2023 Oct 26;34:100737. doi: 10.1016/j.lanepe.2023.100737. eCollection 2023 Nov.
5
A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects.
Molecules. 2023 Feb 13;28(4):1762. doi: 10.3390/molecules28041762.
6
Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating infections.
Front Pharmacol. 2022 Nov 14;13:1035841. doi: 10.3389/fphar.2022.1035841. eCollection 2022.
7
Lefamulin.
Hosp Pharm. 2022 Dec;57(6):704-711. doi: 10.1177/0018578719897071. Epub 2020 Jan 2.
8
Molecular Mechanisms of Drug Resistance and Epidemiology of Multidrug-Resistant Variants of .
Int J Mol Sci. 2022 Sep 10;23(18):10499. doi: 10.3390/ijms231810499.
9
Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches.
Emerg Infect Dis. 2022 Aug;28(8). doi: 10.3201/eid2808.220094.
10
Tissue Distribution of [C]-Lefamulin into the Urogenital Tract in Rats.
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0035522. doi: 10.1128/aac.00355-22. Epub 2022 Jul 11.
本文引用的文献
1
Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant Neisseria gonorrhoeae.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01497-17. Print 2017 Nov.
2
A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism.
Sci Rep. 2016 Dec 13;6:39004. doi: 10.1038/srep39004.
3
In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China.
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.02008-16. Print 2017 Feb.
4
Pleuromutilins: Potent Drugs for Resistant Bugs-Mode of Action and Resistance.
Cold Spring Harb Perspect Med. 2017 Jan 3;7(1):a027110. doi: 10.1101/cshperspect.a027110.
5
Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid.
J Antimicrob Chemother. 2016 Apr;71(4):1022-6. doi: 10.1093/jac/dkv442. Epub 2016 Jan 7.
6
Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting.
PLoS One. 2015 Dec 8;10(12):e0143304. doi: 10.1371/journal.pone.0143304. eCollection 2015.
7
An outbreak of high-level azithromycin resistant Neisseria gonorrhoeae in England.
Sex Transm Infect. 2016 Aug;92(5):365-7. doi: 10.1136/sextrans-2015-052312. Epub 2015 Nov 24.
8
Management of Mycoplasma genitalium infections - can we hit a moving target?
BMC Infect Dis. 2015 Aug 19;15:343. doi: 10.1186/s12879-015-1041-6.
9
Sexually transmitted diseases treatment guidelines, 2015.
MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.
10
Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens.
Clin Infect Dis. 2015 Apr 15;60(8):1228-36. doi: 10.1093/cid/ciu1162. Epub 2014 Dec 23.
Zotero 插件